Search results: (10000)
News Continuous Infusion of Tiapride in the Treatment of Hyperactive Delirium – Case Study
Spanish authors recently published a case study of a young man with pharmacologically unmanageable agitation delirium following multiple injuries from a traffic accident, which resolved within 3 days with continuous infusion of tiapride.
News Long-term Safety and Efficacy of Ozanimod in the Treatment of Relapsing Forms of MS
Ozanimod is classified as a modulator of sphingosine-1-phosphate (S1P) receptors types 1 and 5. It is approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) and moderate to severe ulcerative colitis (UC) and continues to undergo intensive clinical research. The DAYBREAK open-label, single-arm study for participants with RRMS from previous trials with ozanimod was scheduled to be completed by January 2023, and its final results can therefore be expected soon. The following article presents the interim analysis results of this study 5 years after initiation.